219 Prevalence of genomic alterations in XernaTM tumor microenvironment subtypes in colorectal cancer patients

• Laura Benjamin,
• Mark Uhlik,
• Frederick L Baehner,
• Jessica Aldrich,
• Luka Ausec,
• Gargi D Basu,
• Janine LoBello,
• Snehal G Thakkar,
• Matthew Halbert,
• Patrick Eimerman,
• Cynthia A Flannery,
• Nishitha Therala,
• David W Hall,
• Daniel Pointing,
• Lea Vohar,
• Roman Lustrik,
• Seema Iyer

Affiliations

Laura Benjamin

UCL Laboratory of Molecular and Cell Biology, London, UK

Mark Uhlik

1Biothera Pharmaceuticals, Eagan, MN, USA

Frederick L Baehner

Departments of Pathology and Laboratory Medicine, University of California, San Francisco, California, USA

Jessica Aldrich

Translational Genomics Research Institute;

Luka Ausec

5Genialis Inc., Boston, MA, USA

Gargi D Basu

1Exact Sciences, Phoenix, AZ, USA

Janine LoBello

1Exact Sciences, Phoenix, AZ, USA

Snehal G Thakkar

1Exact Sciences, Phoenix, AZ, USA

Matthew Halbert

2Exact Sciences, Madison, WI, USA

Patrick Eimerman

2Exact Sciences, Madison, WI, USA

Cynthia A Flannery

3Exact Sciences, Redwood City, CA, USA

Nishitha Therala

3Exact Sciences, Redwood City, CA, USA

David W Hall

1Exact Sciences, Phoenix, AZ, USA

Daniel Pointing

5Genialis Inc., Boston, MA, USA

Lea Vohar

5Genialis Inc., Boston, MA, USA

Roman Lustrik

5Genialis Inc., Boston, MA, USA

Seema Iyer

7OncXerna Therapeutics, Bloomfield, NJ, USA